WHO Recommends Global Use of Rotavirus Vaccines.Decision Could Help Protect Millions of Children in Africa and Asia from Lethal Diarrheal Disease
GENEVA & SEATTLE -- The World Health Organization (WHO) has recommended that rotavirus rotavirus /ro·ta·vi·rus/ (ro´tah-vi?rus) any member of the genus Rotavirus. ro´taviral
Rotavirus /Ro·ta·vi·rus/ (ro´tah-vi?rus vaccination be included in all national immunization immunization: see immunity; vaccination. programmes in order to provide protection against a virus that is responsible for more than 500,000 diarrheal deaths and two million hospitalizations annually among children. More than 85 percent of these deaths occur in developing countries in Africa and Asia. This new policy will help ensure access to rotavirus vaccines in the world's poorest countries.
The new recommendation by the WHO's Strategic Advisory Group of Experts (SAGE), extends an earlier recommendation made in 2005 on vaccination in the Americas and Europe, where clinical trials had demonstrated safety and efficacy in low- and intermediate-mortality populations. New data from clinical trials which evaluated vaccine efficacy Vaccine efficacy is defined as the reduction in the incidence of a disease among people who have received a vaccine compared to the incidence in unvaccinated people. The efficacy of a new vaccine is measured in phase III clinical trials by giving one group of people a vaccine and in countries with high child mortality has led to the recommendation for global use of the vaccine. This is reported in the Weekly Epidemiological Review published on June 5, 2009.
"This is a tremendous milestone in ensuring that vaccines against the most common cause of lethal diarrhea reach the children who need them most," noted Dr. Thomas Cherian, Coordinator of the Expanded Programme on Immunization, WHO Department of Immunization, Vaccines, and Biologicals.
The GAVI GAVI Global Alliance for Vaccines and Immunization Alliance, vaccine manufacturers, and the public health community made an unprecedented commitment to understand how these vaccines would work in developing-world conditions. The clinical trial, funded in part by GAVI and conducted by PATH, WHO, GlaxoSmithKline (GSK GSK GlaxoSmithKline plc (pharmaceutical company)
GSK Glycogen Synthase Kinase
GSK Gruppentraining Sozialer Kompetenzen (Germany)
GSK Greenland Shark (FAO fish species code) ), and research institutions in high-mortality, low-socioeconomic settings of South Africa South Africa, Afrikaans Suid-Afrika, officially Republic of South Africa, republic (2005 est. pop. 44,344,000), 471,442 sq mi (1,221,037 sq km), S Africa. and Malawi, found that rotavirus vaccine significantly reduced severe diarrhea episodes due to rotavirus.
"This WHO recommendation clears the way for vaccines that will protect children in the developing world from one of the most deadly diseases they face," said Dr. Tachi Yamada This article or section is written like an .
Please help [ rewrite this article] from a neutral point of view.
Mark blatant advertising for , using . Dr. , President of the Global Health Program at the Bill & Melinda Gates Melinda French Gates (born Melinda Ann French on August 15, 1964) is a former unit manager for several Microsoft products: Publisher, Microsoft Bob, Encarta, and Expedia. In 1994, she married Bill Gates, founder, chairman, and former chief software architect of Microsoft. Foundation. "We need to act now to deliver vaccines to children in Africa and Asia, where most rotavirus deaths occur."
In 2006, the GAVI Alliance added rotavirus vaccines to its portfolio of vaccines for which it provides financial support to developing countries, underscoring GAVI's commitment to reduce the traditional 15- to 20-year lag between the introduction of new vaccines in wealthy countries and their availability in the developing world. Today, WHO's global recommendation paves the way for low-income countries in Africa and Asia to apply to GAVI for introduction of rotavirus vaccines-- just three years after new rotavirus vaccines became available in the US, Europe, and Latin America.
"The GAVI Alliance welcomes this exciting recommendation," said GAVI CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dr. Julian Lob-Levyt. "It represents another important step in our ability to achieve significant impact on under-five deaths in the world's poorest communities and make progress towards the Millennium Development Goals “MDG” redirects here. For other uses, see MDG (disambiguation).
The Millennium Development Goals are eight goals that 192 United Nations member states have agreed to try to achieve by the year 2015. . We are extremely excited about the potential to offer African and Asian countries funding to introduce rotavirus vaccines."
Because oral vaccines can have variable efficacy in different populations, it was important to demonstrate vaccine performance in high-mortality settings. The studies in Africa were conducted among populations with high infant and child mortality, poor sanitary conditions, high diarrheal disease mortality, and high maternal HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. prevalence.
"The new evidence and the WHO recommendation are major breakthroughs for the health of our children," said Dr. Oyewale Tomori, Vice Chancellor of Redeemer's University, Nigeria, who has served as Regional Laboratory Coordinator for the World Health Organization (Africa Region). "Too many of our children are dying from rotavirus and other causes of diarrhea Diarrhea (in American English) or diarrhoea (in British English) is a condition in which the sufferer has frequent watery, loose bowel movements.
Many things can cause diarrhea, which can make diagnosis complex. . We urgently need these lifesaving vaccines against rotavirus."
The clinical trial investigators from Malawi and South Africa will present and publish their data on the GSK Rotarix(TM) vaccine later this summer. Clinical trial sites in Bangladesh and Vietnam--along with sites in Ghana, Mali, and Kenya--evaluated the performance of Merck's rotavirus vaccine, RotaTeq[R], and data are expected in Fall 2009. While efficacy data from Asian countries are forthcoming, SAGE recommended rotavirus vaccines for all populations, including Asia, since available evidence indicates that efficacy data can be extrapolated to populations with similar mortality patterns, regardless of geographic location.
Because there are many causes of diarrheal disease, SAGE emphasized the importance of providing rotavirus vaccination in the context of a comprehensive diarrheal disease control strategy, including improvement of water quality, hygiene, and sanitation; provision of oral rehydration solution Oral Rehydration Solution (ORS)
A liquid preparation developed by the World Health Organization that can decrease fluid loss in persons with diarrhea. Originally developed to be prepared with materials available in the home, commercial preparations have recently and zinc supplements; and overall improved case management.
WHO, UNICEF UNICEF (y`nĭsĕf'), the United Nations Children's Fund, an affiliated agency of the United Nations. , and other GAVI partners are working together in a new accelerated and integrated approach to combat rotavirus diarrhea and pneumonia, the two biggest vaccine-preventable diseases which together account for more than 35 percent of all child deaths each year, the majority of which are in the developing world.
Weekly Epidemiological Record: http://www.who.int/wer/en/index.html
Statements of Support from select global health experts: http://www.path.org/news/pr090605-who-rotavirus.php#support